Evoke Pharma, Inc. (EVOK) financial statements (2020 and earlier)

Company profile

Business Address 420 STEVENS AVENUE
SOLANA BEACH, CA 92075
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments658991424
Cash and cash equivalents658991424
Prepaid expense1000110
Deferred costs     0 
Other current assets   0 0 
Other undisclosed current assets     (0) 
Total current assets:6689101524
Noncurrent Assets
Operating lease, right-of-use asset0
Other noncurrent assets0000001
Total noncurrent assets:0000001
TOTAL ASSETS:6689101525
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1010110
Employee-related liabilities1111111
Other undisclosed accounts payable and accrued liabilities0(1)0(0)00(0)
Debt0   001
Due to related parties     0 
Other liabilities     0 
Other undisclosed current liabilities1111111
Total current liabilities:2221222
Noncurrent Liabilities
Long-term debt and lease obligation    442
Long-term debt, excluding current maturities    442
Liabilities, other than long-term debt     00
Deferred revenue and credits   00
Other undisclosed noncurrent liabilities  44 (0) 
Total noncurrent liabilities:  44442
Total liabilities:2266664
Stockholders' equity
Stockholders' equity attributable to parent, including:44243921
Common stock0000000
Additional paid in capital90837363524544
Accumulated deficit(86)(79)(71)(59)(48)(36) 
Other undisclosed stockholders' equity attributable to parent      (23)
Total stockholders' equity:44243921
TOTAL LIABILITIES AND EQUITY:6689101525

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(7)(8)(11)(11)(12)(13)(3)
Operating loss:(7)(8)(11)(11)(12)(13)(3)
Nonoperating income (expense)00(1)(0)(0)(0)(0)
Interest and debt expense    (1)(0)(0)
Net loss:(7)(8)(12)(11)(13)(13)(3)
Other undisclosed net income attributable to parent    100
Net loss available to common stockholders, diluted:(7)(8)(12)(11)(12)(13)(3)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(7)(8)(12)(11)(13)(13)(3)
Comprehensive loss, net of tax, attributable to parent:(7)(8)(12)(11)(13)(13)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: